Interacting Drugs |
Carboplatin Carboplatin vs SORAfenib |
Security Level |
|
Mechanism |
SORAfenib: May enhance the adverse/toxic effect of CARBOplatin. |
Management |
Concurrent sorafenib with carboplatin and placlitaxel in patients with squamous cell lung cancer is contraindicated. Use in other settings is not specifically contraindicated but should be approached with added caution. |
Carboplatin vs SORAfenib
Post Review about Carboplatin vs SORAfenib Click here to cancel reply.
Other Interactions of Carboplatin
Other Interactions of SORAfenib
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.